Table 2. Tumor growth rate estimated in T2WI and contrast-enhancement T1WI MRI.
| T2WI (N = 109) | CE-T1WI (N = 54a) | |||
| Mean (95% CI) | Median (IQR) | Mean (95% CI) | Median (IQR) | |
| Absolute volume change (cm3) | 24.5 (19.2-29.8) | 16.1 (4.8-34.1) | 22.9 (17.1-28.6) | 18.0 (7.6-34.1) |
| Relative volume change (%) | 37.8 (32.9-42.8) | 35.0 (18.0-61.5) | 54.0 (45.1-62.9) | 55.5 (30.0-86.0) |
| Volume-based tumor growth rate | ||||
| VDT (days) | 274.6 (91.3-457.9) | 76.9 (43.6-222.9) | 112.1 (42.6-181.6) | 46.8 (23.3-101.1) |
| eVDT (days) | 63.4 | - | 39.8 | - |
| SGR (%) | 1.0 (0.8-1.3) | 1.0 (0 -1.0) | 1.6 (1.3-2.1) | 1.7 (0.01-0.3) |
| MTD-based tumor growth rate | ||||
| VDE (mm/year) | 53.2 (43.1-63.4) | 40.37 (11.7-76.0) | 75.2 (57.9-92.6) | 61.10 (30.8-114.1) |
| eVDE (mm/year) | 51.6 (41.5-61.0) | - | 64.3 (47.8-80.7) | - |
Abbreviations: CE, contrast-enhanced; CI, confidence interval; IQR, interquartile range; MTD, mean tumor diameter; VDT, volume doubling time; eVDT, equivalent VDT; SGR, specific growth rate; VDE, velocity of diameter expansion; eVDE, equivalent VDE.
a. The other 55 patients received a single CE- T1WI MRI before surgery.